In 238 Japanese adults with obesity disease, oral orforglipron 6, 12 or 36 mg reduced bodyweight by 5.9%, 8.7% and 7.9% at 72 weeks vs 0.6% with placebo (all p<0.0001); adverse events were mostly mild-to-moderate gastrointestinal symptoms.
RCTn = 238
Yokote et al. Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial